Minimally modified low-density lipoprotein upregulates the ETB and α1 receptors in mouse mesenteric arteries in vivo by activating the PI3K/Akt pathway.
J Pharm Pharmacol
; 71(6): 937-944, 2019 Jun.
Article
em En
| MEDLINE
| ID: mdl-30663067
ABSTRACT
OBJECTIVES:
The current study aimed to explore whether minimally modified low-density lipoprotein (mmLDL) via tail vein injection upregulates the ETB and α1 receptors in mouse mesenteric arteries by activating the PI3K/Akt pathway.METHODS:
The contraction curves of the mesenteric arteries caused by sarafotoxin 6c (S6c, ETB receptor agonist) and phenylephrine (PE, α1 receptor agonist) were measured by a myograph system. Serum oxLDL was detected using enzyme-linked immunosorbent assays. The levels of the ETB receptor, the α1 receptor, PI3K, p-PI3K and p-Akt were detected using real-time polymerase chain reaction and Western blot analyses. KEYFINDINGS:
Minimally modified low-density lipoprotein noticeably enhanced the contraction effect curves of S6c and PE, with significantly increased Emax values (P < 0.01), compared to those of the control group. This treatment significantly increased the mRNA expression and protein levels of the ETB and α1 receptors and the protein levels of p-PI3K and p-Akt in the vessel wall (P < 0.01). LY294002 inhibited the effect of mmLDL.CONCLUSIONS:
An increase in mmLDL activated the PI3K/Akt pathway, which upregulated the expression of the ETB and α1 receptors and enhanced the ETB and α1- receptor-mediated contractile function.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptores Adrenérgicos alfa 1
/
Receptor de Endotelina B
/
Lipoproteínas LDL
/
Artérias Mesentéricas
Limite:
Animals
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article